Neurophet and AriBio to develop next-gen Alzheimer's diagnosis platform

Neurophet, an AI solution provider for brain diseases, has announced a collaboration with AriBio, a biopharmaceutical company focused on neurodegenerative disease treatments. This partnership is set to develop a cutting-edge platform for diagnosing Alzheimer's disease. The initiative aims to integrate Neurophet's brain MRI analysis technology with fluid biomarker data from AriBio's global Phase 3 clinical trial for early Alzheimer's detection.

Traditionally, diagnosing Alzheimer’s involves either an expensive amyloid-PET scan or a cerebrospinal fluid (CSF) test, which requires a painful lumbar puncture. These methods present significant barriers to accessibility and comfort for patients. Neurophet and AriBio aim to overcome these challenges by developing a platform that predicts the risk of amyloid beta protein positivity early, using MRI analysis alongside blood-based biomarker tests. This innovative approach intends to minimize the need for amyloid-PET scans, thereby making Alzheimer’s disease testing more accessible and less invasive.

Jake Junkil Been, CEO of Neurophet, emphasized the importance of participating in AriBio's global Phase 3 clinical trial of AR1001. He noted that the trial provides a broad range of medical data, supporting meaningful research in multiple fields. If successful, this new platform could substantially reduce the costs associated with diagnosing and treating dementia while enhancing patient convenience.

Jai Jun Choung, CEO of AriBio, highlighted the company's efforts to develop a safe and convenient oral tablet for Alzheimer’s patients. He expressed optimism that the collaboration with Neurophet would further improve diagnostic accessibility and convenience for both patients and their families.

Neurophet has officially joined AriBio’s global Phase 3 clinical trial of AR1001, an oral treatment for Alzheimer's disease. Neurophet’s role includes identifying eligible patients for the trial and assessing the treatment effects using its brain imaging analysis technology. Both companies are conducting joint research and business development, leveraging data from AR1001 clinical trials, which include medical imaging, blood, and CSF data from a large, multinational cohort.

Neurophet, founded in 2016 by Jake Junkil Been and Donghyeon Kim, specializes in developing AI-based solutions for brain disease diagnosis and treatment. The company’s key products include "Neurophet AQUA" for brain MRI analysis, "Neurophet SCALE PET" for brain PET image analysis, and "Neurophet tES/TMS LAB" for planning brain stimulation treatments. Committed to aiding patients with brain diseases, Neurophet leverages its expertise in neuroscience to explore brain health and innovate AI-driven solutions for these conditions.

Through this collaboration, both Neurophet and AriBio aim to make significant advancements in the early diagnosis and treatment of Alzheimer’s disease, potentially revolutionizing the current methodologies and making a substantial impact on patient care and healthcare costs.